bioRxiv ScienceSearch

bioRxiv · 10.1101/2020.07.14.202085

10 Years of EPOC: A scoping review of Emotiv's portable EEG device

Abstract

BACKGROUNDCommercially-made low-cost electroencephalography (EEG) devices have become increasingly available over the last decade. One of these devices, Emotiv EPOC, is currently used in a wide variety of settings, including brain-computer interface (BCI) and cognitive neuroscience research. PURPOSEThe aim of this study was to chart peer-reviewed reports of Emotiv EPOC projects to provide an informed summary on the use of this device for scientific purposes. METHODSWe followed a five-stage methodological framework for a scoping review that included a systematic search using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) guidelines. We searched the following electronic databases: PsychINFO, MEDLINE, Embase, Web of Science, and IEEE Xplore. We charted study data according to application (BCI, clinical, signal processing, experimental research, and validation) and location of use (as indexed by the first authors address). RESULTSWe identified 382 relevant studies. The top five publishing countries were the United States (n = 35), India (n = 25), China (n = 20), Poland (n = 17), and Pakistan (n = 17). The top five publishing cities were Islamabad (n = 11), Singapore (n = 10), Cairo, Sydney, and Bandung (n = 7 each). Most of these studies used Emotiv EPOC for BCI purposes (n = 277), followed by experimental research (n = 51). Thirty-one studies were aimed at validating EPOC as an EEG device and a handful of studies used EPOC for improving EEG signal processing (n = 12) or for clinical purposes (n = 11). CONCLUSIONSIn its first 10 years, Emotiv EPOC has been used around the world in diverse applications, from control of robotic limbs and wheelchairs to user authentication in security systems to identification of emotional states. Given the widespread use and breadth of applications, it is clear that researchers are embracing this technology.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Williams, N., McArthur, G. M., Badcock, N. A.. 2020-07-14. 10 Years of EPOC: A scoping review of Emotiv's portable EEG device. https://doi.org/10.1101/2020.07.14.202085

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

The Unreasonable Effectiveness of Cell Types in Describing Neuronal Physiological Features

Single-cell RNA sequencing (scRNA-seq) captures detailed gene expression profiles at scale, while patch-clamp recordings measure intrinsic neuronal electrophysiological properties. Modeling the relations between these two modalities remains a challenge. Here, we compare how well electrophysiological features can be predicted by traditional transcriptomic cell type classification, representations derived from a foundational model (scGPT) pretrained on large-scale scRNA-seq datasets, ion channel-coding genes, and highly variable genes. Using paired transcriptomic and electrophysiological patch-sequencing data from 495 human neurons from neurosurgical tissue, we find that cluster-level cell type representations consistently outperform highly variable gene selection, ion channel gene selection, and context-enriched scGPT embeddings. Notably, performance varies across model architectures and initializations, and the best results are obtained by combining the outputs of separate cell type and scGPT-based models. Together, these findings suggest that traditional discrete cellular classification is highly effective in predicting physiological features. For maximum performance it can be complemented by pretrained transformer models.

neuroscience

A nonlinear inhibition pathway underlying cortical responses to tuned holographic optogenetic perturbations

Optogenetics enables causal manipulation of cortical activity. Perturbation responses can be counterintuitive due to network interactions, making theory essential for predicting them. Existing approaches often rely on linear approximations, which fail for many biologically relevant perturbations. Here we develop a nonlinear theory of responses to holographic perturbations in cell-type-specific recurrent networks with structured connectivity. We fit a nonlinear model to mouse V1 data, which shows cotuned-ensemble suppression: perturbing spatially clustered neurons with similar preferred orientations yields markedly stronger short-range suppression than perturbing untuned ensembles. We show that cotuned-ensemble suppression arises from a feature-tuned, nonlinear inhibition pathway implicating somatostatin-positive (SST) interneurons. The theory predicts that cotuned ensembles suppress parvalbumin-positive (PV) neurons but facilitate SST neurons, and links the degree of cotuned-ensemble suppression or facilitation to the variance of the SST response. This framework identifies mechanisms by which nonlinear inhibition sculpts cortical dynamics and establishes a predictive basis for targeted optogenetic interventions.

neuroscience

Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimers disease

The apolipoprotein E {varepsilon}4 (APOE {varepsilon}4) allele is the strongest genetic risk factor for late-onset Alzheimers disease (AD). However, the underlying molecular mechanisms remain unclear. This study included 1691 participants from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP), 1226 participants from the Accelerating Medicines Partnership - Alzheimers Disease (AMP-AD) Diverse Cohorts Study, and 735 participants from the Alzheimers Disease Neuroimaging Initiative (ADNI). To characterise APOE {varepsilon}4 molecular effects, we analysed proteomic data from plasma, cerebrospinal fluid (CSF), and induced pluripotent stem cell (iPSC)-derived astrocytes and neurons, as well as transcriptomic and proteomic data from multiple brain regions. The association of APOE {varepsilon}4 with AD neuropathology was also examined. APOE {varepsilon}4 carriers shared a plasma proteomic signature enriched for immune processes, irrespective of AD diagnosis. A machine learning classifier trained on this signature discriminated APOE {varepsilon}4 carriers from non-carriers in an independent cohort using CSF proteomics. APOE {varepsilon}4 carriage was associated with higher Braak stages and Consortium to Establish a Registry for Alzheimers Disease (CERAD) score. However, only limited APOE {varepsilon}4-associated transcriptomic and proteomic changes were observed in bulk brain tissue, with poor cross-layer concordance. Proteomic analyses of iPSC-derived astrocytes and neurons further revealed cell-type-specific APOE {varepsilon}4-associated changes. APOE {varepsilon}4 is associated with a consistent proteomic signature across plasma and CSF. Its molecular effects in the brain differ across cell types, brain regions and molecular layers. These findings support the need for cell-type-resolved multi-omic studies to elucidate how APOE {varepsilon}4 confers AD risk.

neuroscience